Veru Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for cardiometabolic and inflammatory diseases. Its pipeline includes enobosarm, an oral selective androgen receptor modulator (SARM) being developed to enhance GLP-1 RA weight loss by preserving lean mass and reducing fat, and sabizabulin, a microtubule disruptor for atherosclerotic cardiovascular disease inflammation. On December 30, 2024, Veru sold its FDA-approved FC2 Female Condom commercial product.
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-12-17 | 2025-09-30 | 0001437749-25-038089 | EDGAR | 73K words |
| 2024-12-16 | 2024-09-30 | 0001437749-24-037576 | EDGAR | — |
| 2023-12-08 | 2023-09-30 | 0000863894-23-000017 | EDGAR | — |
| 2022-12-05 | 2022-09-30 | 0000863894-22-000017 | EDGAR | — |
| 2021-12-02 | 2021-09-30 | 0000863894-21-000013 | EDGAR | — |
| 2020-12-10 | 2020-09-30 | 0000863894-20-000021 | EDGAR | — |
| 2019-12-12 | 2019-09-30 | 0000863894-19-000014 | EDGAR | — |
| 2018-12-13 | 2018-09-30 | 0000863894-18-000011 | EDGAR | — |
| 2018-01-02 | 2017-09-30 | 0001562762-17-000231 | EDGAR | — |
| 2016-12-12 | 2016-09-30 | 0000863894-16-000032 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-11 | 2025-12-31 | 0001437749-26-003725 | EDGAR | 26K words |
| 2025-08-12 | 2025-06-30 | 0001437749-25-026072 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001437749-25-015330 | EDGAR | — |
| 2025-02-13 | 2024-12-31 | 0001437749-25-003734 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001437749-24-025338 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000863894-24-000011 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0000863894-24-000008 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000863894-23-000009 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000863894-23-000006 | EDGAR | — |
| 2023-02-09 | 2022-12-31 | 0000863894-23-000003 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000863894-22-000013 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000863894-22-000009 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001437749-26-008216 | EDGAR | 14K words |
| 2026-02-11 | 0001193125-26-045527 | EDGAR | — |
| 2025-12-17 | 0001193125-25-321663 | EDGAR | — |
| 2025-10-30 | 0001193125-25-258565 | EDGAR | — |
| 2025-09-26 | 0001437749-25-029912 | EDGAR | — |
| 2025-08-27 | 0001437749-25-027858 | EDGAR | — |
| 2025-08-12 | 0001437749-25-026037 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178463 | EDGAR | — |
| 2025-07-25 | 0001437749-25-023521 | EDGAR | — |
| 2025-05-08 | 0001193125-25-115453 | EDGAR | — |
316 total filings indexed. 284 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000863894 |
| Ticker | VERU |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | WI |
| Website | https://www.verupharma.com |
| Listed | 1990-06-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report